Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.35 |
| ▸ | TYK2 | P29597 | 7/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161766 | 0.93 | KMT2A (0.35) | SSTR3PDE1BTYK2F10NR3C1 | |
| SCHEMBL31161788 | 0.90 | TYK2 (0.37) | SSTR3PDE1BTYK2F10CNR1 | |
| SCHEMBL16794653 | 0.89 | CNR2 (0.41) | TYK2F10ALDH1A1MCHR1CNR1 | |
| SCHEMBL16794640 | 0.89 | TYK2 (0.40) | SSTR3PDE1BTYK2F10NR3C1 | |
| SCHEMBL16794641 | 0.89 | TYK2 (0.40) | SSTR3PDE1BTYK2F10NR3C1 | |
| SCHEMBL16812488 | 0.89 | TYK2 (0.40) | SSTR3PDE1BTYK2F10NR3C1 | |
| SCHEMBL26101957 | 0.89 | TYK2 (0.40) | SSTR3PDE1BTYK2F10NR3C1 | |
| SCHEMBL16794701 | 0.88 | YAP1 (0.41) | PDE1BTYK2F10LMNAMEN1 | |
| SCHEMBL16812491 | 0.88 | YAP1 (0.43) | F10LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL16812485 | 0.85 | HPGDS (0.41) | PDE1BTYK2F10NR3C1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | SSTR3 2294/4885PDE1B 3074/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.